Cardiac arrhythmias are among the leading causes of mortality. They often arise from
alterations in the electrophysiological properties of cardiac cells and their underlying ionic …

More than 2,000,000 individuals worldwide have had coronavirus 2019 disease infection
(COVID-19), yet there is no effective medical therapy. Multiple off-label and investigational …

The implementation of the ICH S7B and E14 guidelines has been successful in preventing
the introduction of potentially torsadogenic drugs to the market, but it has also unduly …

The early and efficient assessment of cardiac safety liabilities is essential to confidently
advance novel drug candidates. This article discusses evolving mechanistically based …

Key points Induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CMs) capture
patient‐specific genotype–phenotype relationships, as well as cell‐to‐cell variability of …

Unexpected cardiac adverse effects are the leading causes of discontinuation of clinical
trials and withdrawal of drugs from the market. Since the original observations in the mid …

Heart disease is a significant burden on global health care systems and is a leading cause
of death each year. To improve our understanding of heart disease, high quality disease …

Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs
(AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia …

There is a growing appreciation for differences in epidemiology, treatment, and outcomes of
cardiovascular conditions by sex. Historically, cardiovascular clinical trials have under …

Across individuals within a population, several levels of variability are observed, from the
differential expression of ion channels at the molecular level, to the various action potential …